On this page

Effective ammonia control for confident living1

RAVICTI is the only FDA-approved oral therapy clinically studied over the long term (12 months) in pediatric and adult patients with urea cycle disorders (UCDs).1

Review the RAVICTI clinical trial program

  • In Study 6 (right), mean venous ammonia levels in patients starting treatment at less than 2 months of age (n=16)b were less than 100 μmol/L during treatment with RAVICTI for up to 24 months (range, 35-94 μmol/L).1
  • In this study, 16 of 16 (100%) patients less than 2 months of age successfully transitioned to RAVICTI within 7 days (4 days of transition followed by 3 days of observation).1,c
  • Of 16 patients starting treatment at less than 2 months of age in this 24-month study, 5 patients (31%) reported a total of 7 hyperammonemic crises, all of which occurred in patients less than 1 month of age.1

RAVICTI provides ammonia control in pediatric patients less than 2 months of age with UCDs1,a

Graph showing efficacy of RAVICTI ammonia level control in UCD patients less than 2 months old Click to enlarge

aAn uncontrolled, open-label study was conducted in 16 children less than 2 months of age to assess transition to RAVICTI over a period of 7 days, followed by monthly assessment of ammonia control and hyperammonemic crises over a 24-month period. Ammonia values across different laboratories were normalized to a common normal pediatric range of 28 to 57 μmol/L.1

bSixteen, 14, 12, 6, and 3 patients completed 1, 3, 6, 12, and 18 months of treatment, respectively (median exposure of 10 months [range, 2 to 20 months]).1

cSuccessful transition was defined as no signs and symptoms of hyperammonemia and a venous ammonia value less than 100 μmol/L.1

  • In Study 6 (right), mean venous ammonia levels in patients 2 months to less than 2 years of age (n=10)i were less than 100 μmol/L during treatment with RAVICTI for up to 6 months (range, 53-93 μmol/L).1
  • In Study 6, 9 of 10 (90%) patients 2 months to less than 2 years of age successfully transitioned to RAVICTI within 7 days.1,j
  • In Studies 4/4E and 5, mean venous ammonia levels in patients 2 months to less than 2 years of age (n=7)k were less than 100 μmol/L during treatment with RAVICTI for up to 12 months (range, 31-65 μmol/L).1
  • Of the 17 pediatric patients 2 months to less than 2 years of age in 3 open-label studies, 7 patients (41%) reported a total of 11 hyperammonemic crises.1

RAVICTI provides ammonia control in pediatric patients 2 months to less than 2 years of age with UCDs1,h

Graph showing efficacy of RAVICTI ammonia level control in pediatric patients from 2 months to less than 2 years Click to enlarge

hUncontrolled, open-label studies were conducted to assess monthly ammonia control and hyperammonemic crises with RAVICTI in pediatric patients 2 months to less than 2 years of age (study 4/4E, study 5, and study 6). Patients in study 5 previously participated in study 4/4E. A total of 17 pediatric patients with UCDs 2 months to less than 2 years of age participated in the studies. Ammonia values across different laboratories were normalized to a common normal pediatric range of 28 to 57 μmol/L.1

iNine, 7, and 7 patients completed 1, 3, and 6 months of treatment, respectively (mean and median exposure of 9 and 9 months, respectively).1

jSuccessful transition was defined as no signs and symptoms of hyperammonemia and a venous ammonia value less than 100 μmol/L.1

kSuccessful transition was defined as no signs and symptoms of hyperammonemia and a venous ammonia value less than 100 μmol/L.1

RAVICTI provides effective 24-hour ammonia control in pediatric patients with UCDs1,l

Graph showing efficacy of RAVICTI 24 hour ammonia level control in UCD pediatric patients from 2 to 17 Click to enlarge

  • In patients with UCDs between 2 and 5 years of age (n=11), the ammonia AUC0–24h value was 632 μmol⋅h/L vs 720 μmol⋅h/L on RAVICTI vs NaPBA, respectively.1
  • In patients 6 to 17 years of age (n=11), the ammonia AUC0–24h value was 604 μmol⋅h/L vs 815 μmol⋅h/L on RAVICTI vs NaPBA, respectively.1
  • Among the 22 patients in these studies, no hyperammonemic crises were reported during treatment with RAVICTI.2

lThe efficacy of RAVICTI in pediatric patients 2 to 17 years of age was evaluated in 2 fixed-sequence, open-label, NaPBA-to-RAVICTI crossover studies (studies 3 and 4). Study 3 was 7 days in duration and study 4 was 10 days in duration. These studies compared blood ammonia levels of patients on RAVICTI with venous ammonia levels of patients on NaPBA in 26 pediatric patients between 2 months and 17 years of age. The AUC0–24h for blood ammonia in 11 pediatric patients 6 to 17 years of age (study 3) and 11 pediatric patients 2 to 5 years of age (study 4) were similar between treatments.1

  • Mean fasting venous ammonia values in pediatric patients (n=26) 6 to 17 years of age were within normal limits (≤35 μmol/L) during long-term treatment with RAVICTI (range, 17–23 μmol/L).1
  • Of the 26 pediatric patients 6 to 17 years of age participating in these 2 trials, 5 patients (19%) reported a total of 5 hyperammonemic crises.1

RAVICTI provides effective ammonia control sustained over 12 months in pediatric patients with UCDs1,m

Graph showing RAVICTI efficacy of sustained ammonia level control over 12 months in pediatric UCD patients Click to enlarge

mLong-term (12-month), uncontrolled, open-label studies were conducted to assess monthly ammonia control and hyperammonemic crises. In 2 studies, a total of 26 pediatric patients 6 to 17 years of age were enrolled, and all but 1 had been converted from NaPBA to RAVICTI. Ammonia values across different laboratories were normalized to a common normal range of 9 to 35 μmol/L.1

RAVICTI provides 24-hour ammonia control in adult patients with UCDs1,n

Graph showing efficacy of RAVICTI for 24 hour ammonia level control in adults with Urea Cycle Disorder Click to enlarge

  • Mean 24-hour area under the curve (AUC0–24h) values during steady-state dosing were 866 μmol⋅h/L and 977 μmol⋅h/L with RAVICTI and NaPBA, respectively (ratio of geometric means, 0.91; 95% CI, 0.8–1.04).1
  • Among the 44 patients in this short-term study, no hyperammonemic crises were reported during treatment with RAVICTI.2

nA randomized, double-blind, active-controlled, crossover, noninferiority study compared RAVICTI with NaPBA by evaluating venous ammonia levels in patients with UCDs who had been on NaPBA prior to enrollment. Forty-four patients were randomized 1:1 to receive either NaPBA for 2 weeks then RAVICTI for 2 weeks, or RAVICTI for 2 weeks then NaPBA for 2 weeks. RAVICTI was noninferior to NaPBA with respect to the AUC0–24h for ammonia.1

  • Mean fasting venous ammonia values in adults (n=51) were within normal limits (≤35 μmol/L) during long-term treatment with RAVICTI (range, 6–30 μmol/L).1
  • Of the 51 adult patients participating in the 12-month, open-label treatment with RAVICTI, 7 patients (14%) reported a total of 10 hyperammonemic crises.1

RAVICTI provides effective ammonia control sustained over 12 months in adult patients with UCDs1,o

Graph showing efficacy of RAVICTI in ammonia control sustained over 12 months for adults with Urea Cycle Disorders Click to enlarge

oA long-term (12-month), uncontrolled, open-label study was conducted to assess monthly ammonia control and hyperammonemic crises. A total of 51 adult patients were in the study and all but 6 had been converted from NaPBA to RAVICTI. Ammonia values across different laboratories were normalized to a common normal range of 9 to 35 μmol/L.1

On this page

Safety profile

The U.S. Food and Drug Administration has approved RAVICTI for use in adult and pediatric patients with UCDs based on its safety and efficacy profiles.1

Adverse events in adult patients with UCDsd

Adverse reactions reported in 2 or more adult patients with UCDs in a short-term clinical trial.1

Chart showing reported adverse reactions for RAVICTI in adult UCD patients in short-term clinical trials Click to enlarge

  • Adverse reactions occurring in at least 10% of adult patients during 12 months of treatment were nausea, vomiting, diarrhea, decreased appetite, dizziness, headache, and fatigue.1
  • Of the 51 adult patients, 7 patients (14%) reported a total of 10 hyperammonemic crises.1

Adverse events in pediatric patients 2 to 17 years of age with UCDse

  • Adverse reactions occurring in at least 10% of pediatric patients 2 to 17 years of age during 12 months of treatment with RAVICTI were upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, and headache.1
  • Of the 26 pediatric patients 6 to 17 years of age, 5 patients (19%) reported a total of 5 hyperammonemic crises.1

Adverse events in pediatric patients 2 months to less than 2 years of age with UCDsf

  • Adverse reactions occurring in at least 10% of pediatric patients 2 months to less than 2 years of age were neutropenia, vomiting, constipation, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash, and papule.1
  • Of the 17 pediatric patients 2 months to less than 2 years of age in 3 open-label studies, 7 patients (41%) reported a total of 11 hyperammonemic crises.1

Adverse events in pediatric patients less than 2 months of age with UCDsg

  • Adverse reactions occurring in at least 10% of pediatric patients less than 2 months of age were vomiting, rash, gastroesophageal reflux, increased hepatic enzymes, feeding disorder (decreased appetite, hypophagia), anemia, cough, dehydration, metabolic acidosis, thrombocytosis, thrombocytopenia, neutropenia, lymphocytosis, diarrhea, flatulence, constipation, pyrexia, lethargy, and irritability/agitation.1
  • Of the 16 pediatric patients less than 2 months of age in an open-label study, 5 patients (31%) reported a total of 7 hyperammonemic crises, all of which occurred in patients less than 1 month of age.1

Phenylacetate (PAA)-associated adverse events

  • The major metabolite of RAVICTI, PAA, is associated with neurotoxicity. In a study of adult patients with cancer who were administered PAA intravenously, signs and symptoms of PAA neurotoxicity, including somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of preexisting neuropathy were observed at plasma PAA concentrations of 500 μg/mL. In this study, adverse reactions were reversible.1
  • In clinical trials, patients with UCDs who had been on NaPBA prior to administration of RAVICTI had peak PAA concentrations after dosing with RAVICTI ranging from 1.6 to 178 μg/mL (mean, 39 μg/mL) in adult patients and from 1 to 410 μg/mL (mean, 70 μg/mL; median, 50 μg/mL) in pediatric patients 2 years of age and older. In pediatric patients 2 months to less than 2 years of age, peak PAA concentrations after dosing with RAVICTI ranged from 1 to 1215 μg/mL (mean, 142 μg/mL; median, 35 μg/mL) and from 96 to 707 μg/mL (mean, 257 μg/mL; median 205 μg/mL) in pediatric patients less than 2 months of age. Some patients with UCDs experienced headache, fatigue, symptoms of peripheral neuropathy, seizures, tremors, and/or dizziness. No correlation between PAA levels and neurotoxicity symptoms was identified but PAA levels were generally not measured at the time of neurotoxicity symptoms.1

Postmarketing experience

The following adverse reactions have been identified during postapproval use of RAVICTI1:

  • Abnormal body odor, including from skin, hair, and urine
  • Retching and gagging
  • Dysgeusia or burning sensation in mouth

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.1

d Assessment of adverse reactions in a randomized, double-blind, active-controlled, crossover study in which 45 adult patients (at least 18 years of age) with UCDs were treated with either RAVICTI or NaPBA for 2 weeks.1

e Assessment of adverse reactions in 2 open-label studies of 26 patients with UCDs 2 to 17 years of age being treated with RAVICTI for 12 months. There were no deaths during these studies.1

f Assessment of adverse reactions in 3 open-label studies of 17 patients with UCDs 2 months to less than 2 years of age (median exposure, 6 months [range, 0.2‑20 months]). One patient developed hyperammonemia during dosing and experienced surgical complications (bowel perforation and peritonitis) following jejunal tube placement; this patient developed hyperammonemic crisis, and subsequently died of sepsis from peritonitis unrelated to drug.1

g Assessment of adverse reactions in 1 open-label study of 16 patients with UCDs who began treatment at less than 2 months of age (median exposure, 10 months [range, 2-20 months]) to assess transition to RAVICTI over a period of 7 days, followed by monthly assessment of ammonia control and hyperammonemic crises over a 24-month period.1

On this page

RAVICTI® (glycerol phenylbutyrate) Oral Liquid has a unique mechanism of action designed for a slow release of phenylbutyrate (PBA)1,3

An alternate vehicle for waste nitrogen removal can help control ammonia, which can fluctuate daily above the upper limit of normal in patients with urea cycle disorders (UCDs).1,4,5

RAVICTI Mechanism of action and the role of phenylbutyrate (PBA) and phenylacetate (PAA)

RAVICTI Mechanism of action and the role of phenylbutyrate (PBA) and phenylacetate (PAA)

Absorption of PBA is approximately 70% to 75% slower when administered as RAVICTI vs sodium phenylbutyrate.1,9

On this page

Effective ammonia control that you can prescribe with confidence1

Help control ammonia with easy-to-administer oral liquid1,p

Nearly tasteless and odorless liquid icon.

Nearly tasteless and odorless liquid1

No pill or powder preparation and minimal dosing steps required icon.

No pill or powder preparation and minimal dosing steps required1

Taken with meals or feedings via oral dosing syringe icon.

Taken with meals or feedings via oral dosing syringe1,q

pOf the 51 adult patients in the 12-month study of RAVICTI, 7 patients (14%) reported a total of 10 hyperammonemic crises. Of the 26 pediatric patients 6 to 17 years of age in both 12-month studies of RAVICTI, 5 patients (19%) reported a total of 5 hyperammonemic crises. Of the 17 pediatric patients 2 months to less than 2 years of age in 3 open-label studies, 7 patients (41%) reported a total of 11 hyperammonemic crises. Of the 16 pediatric patients less than 2 months of age in an uncontrolled, open-label study, 5 patients (31%) reported a total of 7 hyperammonemic crises.1

qFor patients who require a volume of less than 1 mL per dose via nasogastric or gastrostomy tube, the delivered dose may be less than anticipated. Closely monitor these patients using ammonia levels.1

Important reminders

  • For patients 2 years of age and older, the total daily dosage is given in 3 equally divided doses, each rounded up to the nearest 0.5 mL.1
  • The maximum total daily dosage is 17.5 mL (19 g).1
  • For patients less than 2 years of age, the total daily dosage is given in 3 or more doses, each rounded up to the nearest 0.1 mL.1
  • RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).1

How to administer RAVICTI

Administration of RAVICTI is different depending on the age of the patient.1
Please refer to the following videos to review administration instructions.

Watch instructional videos for administration of RAVICTI to pediatric and adult patients by mouth, nastrogastic tube, or g-tube.

Ready to select the dosage?

See the Dosage Calculator for more information on starting RAVICTI, switching from NaPBA, and optimizing RAVICTI dosing.

Use the Dosage Calculator

Physician writing on tablet. Prescribing RAVICTI Get everything you need to know about starting, switching, and refining treatment with RAVICTI.

Hands filling out forms. Support & Resources Learn more about support and resources for your practice and your patients.

Stay informed about RAVICTI® (glycerol phenylbutyrate) Oral Liquid

Sign Up

References: 1. RAVICTI (glycerol phenylbutyrate) Oral Liquid [prescribing information] Horizon. 2. Data on File. Horizon, April 2017. 3. Monteleone JPR, Mokhtarani M, Diaz GA, et al. Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disorders J Clin Pharmacol. 2013;53(7):699-710. doi:10.1002/jcph.92. 4. Lee B, Diaz GA, Rhead W, et al. Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder. Genet Med. 2015;17(7):561-568. doi:10.1038/gim.2014.148. 5. Lichter-Konecki U, Diaz GA, Merritt JL II, et al. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. Mol Genet Metab. 2011;103(4):323-329. doi:10.1016/j.ymgme.2011.04.013. 6. Smith W, Diaz GA, Lichter-Konecki U, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. J Pediatr. 2013;162(6):1228-1234.e1. doi:10.1016/j.jpeds.2012.11.084. 7. Diaz GA, Krivitzky LS, Mokhtarani M, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. Hepatology. 2013;57(6):2171-2179. doi:10.1002/hep.26058. 8. Mokhtarani M, Diaz GA, Rhead W, et al. Elevated phenylacetic acid levels do not correlate with adverse events in patients with urea cycle disorders or hepatic encephalopathy and can be predicted based on the plasma PAA to PAGN ratio. Mol Genet Metab. 013;110(4):446-453. doi:10.1016/j.ymgme.2013.09.017. 9. Longo N, Holt RJ. Glycerol phenylbutyrate for the maintenance treatment of patients with deficiencies in enzymes of the urea cycle. Exp Opin Orphan Drugs. 2017;5(12):999-1010. doi:10.1080/21678707.2017.1405807.

INDICATION and IMPORTANT SAFETY INFORMATION

true

INDICATION

RAVICTI is indicated for the chronic management of patients with UCDs who cannot be managed by diet and supplementation alone. It must be used with dietary protein restriction. RAVICTI is not indicated for the treatment of acute hyperammonemia or for NAGS deficiency.1

RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).

LIMITATIONS OF USE
  • RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels.
  • The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
  • Patients with known hypersensitivity to phenylbutyrate: Reactions include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash.
WARNINGS AND PRECAUTIONS
  • Neurotoxicity: Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels of 500 micrograms/mL or greater. If symptoms of vomiting, nausea, headache, somnolence, or confusion, are present in the absence of high ammonia or other intercurrent illness which explains these symptoms, consider the potential for PAA neurotoxicity which may need reduction in the RAVICTI dosage.
  • Pancreatic Insufficiency or Intestinal Malabsorption: Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely.
ADVERSE REACTIONS

The most common adverse reactions reported in clinical trials (at least 10% of patients) were:

  • Adult patients: diarrhea, flatulence, and headache occurred during 4-week treatment (n=45) with RAVICTI; nausea, vomiting, diarrhea, decreased appetite, dizziness, headache, and fatigue occurred during 12-month treatment (n=51) with RAVICTI.
  • Pediatric patients ages 2 to 17 years: upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, and headache occurred during 12-month treatment (n=26) with RAVICTI.
  • Pediatric patients ages 2 months to less than 2 years: neutropenia, vomiting, constipation, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash, and papule occurred during 12-month treatment (n=17) with RAVICTI.
  • Pediatric patients less than 2 months of age: vomiting, rash, gastroesophageal reflux, increased hepatic enzymes, feeding disorder (decreased appetite, hypophagia), anemia, cough, dehydration, metabolic acidosis, thrombocytosis, thrombocytopenia, neutropenia, lymphocytosis, diarrhea, flatulence, constipation, pyrexia, lethargy, and irritability/agitation occurred during 24-month treatment (n=16) with RAVICTI.
DRUG INTERACTIONS
  • Corticosteroids, valproic acid, or haloperidol may increase plasma ammonia level. Monitor ammonia levels closely.
  • Probenecid may affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA.
  • CYP3A4 substrates with narrow therapeutic index (eg, alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure to the concomitant drug.
  • Midazolam: Use of RAVICTI decreased exposure of midazolam with concomitant use.
USE IN SPECIFIC POPULATIONS
  • Pregnancy: RAVICTI should be used with caution in patients who are pregnant or planning to become pregnant. Based on animal data, RAVICTI may cause fetal harm. Report pregnancies to Horizon at 1‐866‐479‐6742.
  • Lactation: breastfeeding is not recommended during treatment with RAVICTI. There are no data on the presence of RAVICTI in human milk, the effects on the breastfed infant, nor the effects on milk production.

Please see Full Prescribing Information.

INDICATION and IMPORTANT SAFETY INFORMATION

true

INDICATION

RAVICTI is indicated for the chronic management of patients with UCDs who cannot be managed by diet and supplementation alone. It must be used with dietary protein restriction. RAVICTI is not indicated for the treatment of acute hyperammonemia or for NAGS deficiency.1

RAVICTI (glycerol phenylbutyrate) Oral Liquid is indicated for use as a nitrogen-binding agent for chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements).

LIMITATIONS OF USE
  • RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels.
  • The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
  • Patients with known hypersensitivity to phenylbutyrate: Reactions include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash.
WARNINGS AND PRECAUTIONS
  • Neurotoxicity: Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels of 500 micrograms/mL or greater. If symptoms of vomiting, nausea, headache, somnolence, or confusion, are present in the absence of high ammonia or other intercurrent illness which explains these symptoms, consider the potential for PAA neurotoxicity which may need reduction in the RAVICTI dosage.
  • Pancreatic Insufficiency or Intestinal Malabsorption: Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely.
ADVERSE REACTIONS

The most common adverse reactions reported in clinical trials (at least 10% of patients) were:

  • Adult patients: diarrhea, flatulence, and headache occurred during 4-week treatment (n=45) with RAVICTI; nausea, vomiting, diarrhea, decreased appetite, dizziness, headache, and fatigue occurred during 12-month treatment (n=51) with RAVICTI.
  • Pediatric patients ages 2 to 17 years: upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, and headache occurred during 12-month treatment (n=26) with RAVICTI.
  • Pediatric patients ages 2 months to less than 2 years: neutropenia, vomiting, constipation, diarrhea, pyrexia, hypophagia, cough, nasal congestion, rhinorrhea, rash, and papule occurred during 12-month treatment (n=17) with RAVICTI.
  • Pediatric patients less than 2 months of age: vomiting, rash, gastroesophageal reflux, increased hepatic enzymes, feeding disorder (decreased appetite, hypophagia), anemia, cough, dehydration, metabolic acidosis, thrombocytosis, thrombocytopenia, neutropenia, lymphocytosis, diarrhea, flatulence, constipation, pyrexia, lethargy, and irritability/agitation occurred during 24-month treatment (n=16) with RAVICTI.
DRUG INTERACTIONS
  • Corticosteroids, valproic acid, or haloperidol may increase plasma ammonia level. Monitor ammonia levels closely.
  • Probenecid may affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA.
  • CYP3A4 substrates with narrow therapeutic index (eg, alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure to the concomitant drug.
  • Midazolam: Use of RAVICTI decreased exposure of midazolam with concomitant use.
USE IN SPECIFIC POPULATIONS
  • Pregnancy: RAVICTI should be used with caution in patients who are pregnant or planning to become pregnant. Based on animal data, RAVICTI may cause fetal harm. Report pregnancies to Horizon at 1‐866‐479‐6742.
  • Lactation: breastfeeding is not recommended during treatment with RAVICTI. There are no data on the presence of RAVICTI in human milk, the effects on the breastfed infant, nor the effects on milk production.

Please see Full Prescribing Information.